SG145559A1 - Genes and polypeptides relating to human colon cancers - Google Patents

Genes and polypeptides relating to human colon cancers

Info

Publication number
SG145559A1
SG145559A1 SG200601081-3A SG2006010813A SG145559A1 SG 145559 A1 SG145559 A1 SG 145559A1 SG 2006010813 A SG2006010813 A SG 2006010813A SG 145559 A1 SG145559 A1 SG 145559A1
Authority
SG
Singapore
Prior art keywords
genes
human colon
colon cancers
cancers
polypeptides
Prior art date
Application number
SG200601081-3A
Other languages
English (en)
Inventor
Yusuke Nakamura
Yoichi Furukawa
Hideaki Tahara
Tsunoda Takuya
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29740821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG145559(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of SG145559A1 publication Critical patent/SG145559A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG200601081-3A 2002-06-06 2003-06-03 Genes and polypeptides relating to human colon cancers SG145559A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38698502P 2002-06-06 2002-06-06
US41520902P 2002-09-30 2002-09-30
US45101303P 2003-02-28 2003-02-28

Publications (1)

Publication Number Publication Date
SG145559A1 true SG145559A1 (en) 2008-09-29

Family

ID=29740821

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200601081-3A SG145559A1 (en) 2002-06-06 2003-06-03 Genes and polypeptides relating to human colon cancers

Country Status (17)

Country Link
US (4) US7425612B2 (ko)
EP (3) EP1513934B1 (ko)
JP (3) JP4594085B2 (ko)
KR (2) KR101031025B1 (ko)
CN (1) CN100532549C (ko)
AT (1) ATE500326T1 (ko)
AU (2) AU2003241179C1 (ko)
BR (1) BRPI0311822B8 (ko)
CA (1) CA2488404C (ko)
CY (1) CY1112052T1 (ko)
DE (1) DE60336227D1 (ko)
DK (1) DK1513934T3 (ko)
HK (1) HK1083521A1 (ko)
MX (1) MXPA04012225A (ko)
PT (1) PT1513934E (ko)
SG (1) SG145559A1 (ko)
WO (1) WO2003104275A2 (ko)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2361541T3 (es) * 2002-06-06 2011-06-17 Oncotherapy Science, Inc. Genes y polipéptidos relacionados con cánceres de colon humanos.
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
KR101200133B1 (ko) 2004-06-01 2012-11-13 제넨테크, 인크. 항체 약물 접합체 및 방법
JP4628208B2 (ja) * 2004-08-10 2011-02-09 オンコセラピー・サイエンス株式会社 Ｃｘａｄｒｌ１またはｇｃｕｄ１タンパク質を発現する胃癌または結腸直腸癌の治療のためのペプチドワクチン
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
WO2006110581A2 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes
US7989160B2 (en) 2006-02-13 2011-08-02 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
KR100877554B1 (ko) * 2006-03-30 2009-01-07 재단법인 한국원자력의학원 간암 환자 생존기간 예측용 마커, 그를 포함하는 키트 및마이크로어레이, 및 상기 마커를 이용한 간암 환자생존기간 예측 방법
US8188214B2 (en) * 2007-02-28 2012-05-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Brachyury polypeptides and methods for use
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
CN102356155B (zh) 2009-03-18 2016-02-24 肿瘤疗法科学股份有限公司 Neil3肽及包含它的疫苗
EP2448966B1 (en) 2009-07-03 2018-11-14 Avipep Pty Ltd Immuno-conjugates and methods for producing them
IN2012DN03025A (ko) 2009-09-09 2015-07-31 Ct Se Llc
WO2011075786A1 (en) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
BR112012026213B1 (pt) 2010-04-15 2021-12-28 Medimmune Limited Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
NZ611361A (en) * 2010-12-02 2014-10-31 Oncotherapy Science Inc Tomm34 peptides and vaccines including the same
AU2012245073B2 (en) 2011-04-21 2016-02-11 Garvan Institute Of Medical Research Modified variable domain molecules and methods for producing and using them b
CA2833212C (en) 2011-05-12 2020-06-09 Genentech, Inc. Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature peptides
EP2766033B1 (en) 2011-10-14 2019-11-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
KR101877598B1 (ko) 2011-10-14 2018-07-11 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
BR112014020233A2 (pt) * 2012-02-28 2017-07-04 Irm Llc seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
ES2703151T3 (es) 2012-10-12 2019-03-07 Adc Therapeutics Sa Conjugados de anticuerpos de pirrolobenzodiazepinas
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pirrolobenzodiazepine anti-CD22 antibody conjugates
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP2906250B1 (en) 2012-10-12 2018-05-30 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-psma antibody conjugates
ES2660029T3 (es) 2012-10-12 2018-03-20 Medimmune Limited Conjugados de anticuerpo-pirrolobenzodiazepinas
PT2839860T (pt) 2012-10-12 2019-07-29 Medimmune Ltd Pirrolobenzodiazepinas e conjugados das mesmas
SI2906296T1 (en) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
CN103320445B (zh) * 2013-07-11 2017-07-28 重庆市肿瘤研究所 特异性识别胃癌细胞的dna适配子gca‑5及其应用
AU2014307080B2 (en) 2013-08-12 2018-06-07 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo(E)indole dimer antibody-drug conjugate compounds, and methods of use and treatment
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
JP6895254B2 (ja) 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CA2929565A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (en) 2014-09-12 2019-11-20 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
MA40575A (fr) 2014-09-17 2016-03-24 Genentech Inc Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
AU2015352545B2 (en) 2014-11-25 2020-10-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (ja) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
EP3496763A1 (en) 2016-08-11 2019-06-19 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
EP3522933B1 (en) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Methods for preparing antibody drug conjugates
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
SG11201901979SA (en) 2016-11-30 2019-04-29 Advaxis Inc Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
WO2018192944A1 (en) 2017-04-18 2018-10-25 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
AU2018316532B2 (en) 2017-08-18 2022-11-24 Medimmune Limited Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thylanstatin analogs
CA3081710A1 (en) * 2017-11-08 2019-05-16 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
EP3508499A1 (en) 2018-01-08 2019-07-10 iOmx Therapeutics AG Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
US11787857B2 (en) 2018-02-02 2023-10-17 Bio-Techne Corporation Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
WO2020123275A1 (en) 2018-12-10 2020-06-18 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
US20220372138A1 (en) 2019-07-05 2022-11-24 Iomx Therapeutics Ag Antibodies binding igc2 of igsf11 (vsig3) and uses thereof
US20240010720A1 (en) 2020-07-06 2024-01-11 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066689A2 (en) * 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993002227A1 (en) 1991-07-15 1993-02-04 Eco-Tec Limited Process and apparatus for treating fluoride containing acid solutions
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
EP0754225A4 (en) 1993-04-26 2001-01-31 Genpharm Int HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2361743A1 (en) * 1999-02-22 2000-08-31 Michael G. Walker Genes associated with diseases of the colon
AU7721500A (en) * 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001055317A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001055321A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001241541A1 (en) * 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
US20030228584A1 (en) * 2000-03-07 2003-12-11 Tang Y. Tom Novel nucleic acids and polypeptides
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001296301A1 (en) * 2000-09-26 2002-04-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030064411A1 (en) * 2000-12-08 2003-04-03 Herath Herath Mudiyanselage Athula Chandrasiri Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of Alzheimer's disease
CA2453985A1 (en) * 2001-07-17 2003-04-03 Incyte Genomics, Inc. Receptors and membrane-associated proteins
JP2003245084A (ja) * 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066689A2 (en) * 2000-03-07 2001-09-13 Hyseq, Inc. Novel nucleic acids and polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HYPOTHETICAL PROTEIN FLJ20315 *

Also Published As

Publication number Publication date
CA2488404C (en) 2012-11-27
EP2275544A2 (en) 2011-01-19
EP2233572A3 (en) 2011-01-12
AU2003241179A1 (en) 2003-12-22
US7847065B2 (en) 2010-12-07
BR0311822A (pt) 2005-03-29
JP4594085B2 (ja) 2010-12-08
WO2003104275A3 (en) 2004-04-15
US20100016220A1 (en) 2010-01-21
CN100532549C (zh) 2009-08-26
PT1513934E (pt) 2011-05-11
EP1513934A2 (en) 2005-03-16
ATE500326T1 (de) 2011-03-15
AU2003241179B2 (en) 2009-09-03
KR20100123761A (ko) 2010-11-24
CN1675361A (zh) 2005-09-28
KR101031025B1 (ko) 2011-04-25
AU2003241179C1 (en) 2010-11-25
US20120190628A1 (en) 2012-07-26
MXPA04012225A (es) 2005-07-25
KR101077177B1 (ko) 2011-10-27
US20050069930A1 (en) 2005-03-31
DK1513934T3 (da) 2011-05-02
AU2009243506A1 (en) 2009-12-24
BRPI0311822B8 (pt) 2021-05-25
KR20050053530A (ko) 2005-06-08
US7425612B2 (en) 2008-09-16
US7705141B2 (en) 2010-04-27
JP2006507802A (ja) 2006-03-09
CY1112052T1 (el) 2015-11-04
WO2003104275A2 (en) 2003-12-18
JP2012019791A (ja) 2012-02-02
CA2488404A1 (en) 2003-12-18
EP2233572A2 (en) 2010-09-29
DE60336227D1 (de) 2011-04-14
JP5069268B2 (ja) 2012-11-07
HK1083521A1 (en) 2006-07-07
US20090012032A1 (en) 2009-01-08
JP2009183293A (ja) 2009-08-20
EP2275544A3 (en) 2011-03-30
BRPI0311822B1 (pt) 2019-10-29
EP1513934B1 (en) 2011-03-02

Similar Documents

Publication Publication Date Title
SG145559A1 (en) Genes and polypeptides relating to human colon cancers
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
WO2003104276A3 (en) GENES AND POLYPEPTIDES RELATED TO HEPATOCELLULAR OR COLORECTAL CARCINOMA
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2006016525A3 (en) Genes and polypeptides relating to breast cancers
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
DE69936780D1 (de) Antikörper gegen eine lar-phosphatase untereinheit
ATE545699T1 (de) Modifizierte, rekombinante vacciniaviren und deren verwendungen
HUP0302824A2 (hu) Vakcinakészítmények
HK1093674A1 (en) Anti-april monoclonal antibody and its use for the treatment of an immune related disease or cancer
HK1126668A1 (en) Survivin-derived peptides and use thereof
GEP20105022B (en) Use of polypeptides of the cupredoxin family in cancer therapy
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2003066663A3 (en) Peptides for recognition and targeting of glial cell tumors
TW200502247A (en) Genes and polypeptides relating to human colon cancers
WO2007013479A3 (en) Genes and polypeptides relating to prostate cancers
AU2001255734A1 (en) Sigma-2 receptors as biomarkers of tumor cell proliferation
TH82888A (th) ยีนและโพลีเปปไทด์ที่เกี่ยวข้องกับมะเร็งลำไส้ใหญ่คน
WO2005012912A3 (en) Lamp-1 membrane expression by cancer cells
EP2299268A3 (en) Methods and compositions for diagnosing hepatocellular carcinoma
UA36579A (uk) Спосіб формування коло-ректального анастомозу
WO2004058167A3 (en) Breast specific protein expressed in cancer and methods of use thereof